Form 8-K - Current report:
SEC Accession No. 0001140361-25-004971
Filing Date
2025-02-18
Accepted
2025-02-18 07:55:29
Documents
15
Period of Report
2025-02-18
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K ny20043588x1_8k.htm   iXBRL 8-K 26459
2 EXHIBIT 99.1 ny20043588x1_ex99-1.htm EX-99.1 16509
6 ny20043588x1_logo.jpg GRAPHIC 5266
  Complete submission text file 0001140361-25-004971.txt   192457

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA galt-20250218.xsd EX-101.SCH 4018
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE galt-20250218_lab.xml EX-101.LAB 21966
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE galt-20250218_pre.xml EX-101.PRE 16068
17 EXTRACTED XBRL INSTANCE DOCUMENT ny20043588x1_8k_htm.xml XML 4244
Mailing Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071
Business Address 4960 PEACHTREE INDUSTRIAL BOULEVARD SUITE 240 NORCROSS GA 30071 678-620-3186
GALECTIN THERAPEUTICS INC (Filer) CIK: 0001133416 (see all company filings)

EIN.: 043562325 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-31791 | Film No.: 25632761
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)